Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland

ANZ Journal of Surgery

Volumn 83, Issue 3, 2013, Pages 149-154

  Donovan, Peter J ^a,c   Iedema, Joel ^a   Mcleod, Donald S ^a,d   Kubler, Paul ^a   Pillans, Peter ^b,c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Adverse drug event; Haemostatic therapeutic use; Off label use; Recombinant FVIIa; Thromboembolism aetiology

Indexed keywords

BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

AGED; ARTICLE; AUSTRALIA; BLEEDING; FEMALE; HEART SURGERY; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; OFF LABEL DRUG USE; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY;

AGED; CARDIAC SURGICAL PROCEDURES; COAGULANTS; FACTOR VIIA; FEMALE; GUIDELINE ADHERENCE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; POSTOPERATIVE HEMORRHAGE; QUEENSLAND; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84874785570     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/ans.12005     Document Type: Article

References (23)

1. Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul. Fibrinolysis 1998; 9 (Suppl. 1): S61-65.
2. Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am. Soc. Hematol. Educ. Program 2010; 2010: 153-159.
3. Boffard KD, Riou B, Warren B etal. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J. Trauma 2005; 59: 8-15.
4. Gill R, Herbertson M, Vuylsteke A etal. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120: 21-27.
5. Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register. Intern. Med. J. 2008; 38: 156-165.
6. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br. J. Anaesth. 2005; 95: 596-602.
7. Harrison TD, Laskosky J, Jazaeri O, Pasquale MD, Cipolle M. 'Low-dose' recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J. Trauma 2005; 59: 150-154.
8. NovoNordisk. Evaluation of recombinant factor VIIa in patients with severe bleeding (CONTROL). Edition.: Clinical Trials website. [Cited 21 Nov 2011] Available from URL: http://clinicaltrials.gov/ct2/show/results/NCT00184548
9. Moltzan CJ, Anderson DA, Callum J etal. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework. Transfus. Med. 2008; 18: 112-120.
10. Bosch J, Thabut D, Albillos A etal. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008; 47: 1604-1614.
11. Bosch J, Thabut D, Bendtsen F etal. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 1123-1130.
12. Mayer SA, Brun NC, Begtrup K etal. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N. Engl. J. Med. 2008; 358: 2127-2137.
13. Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin. Thromb. Hemost. 2008; 34: 104-112.
14. Phillips LE, McLintock C, Pollock W etal. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth. Analg. 2009; 109: 1908-1915.
15. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N. Engl. J. Med. 2010; 363: 1791-1800.
16. Diringer MN, Skolnick BE, Mayer SA etal. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008; 39: 850-856.
17. Hsia CC, Zurawska JH, Tong MZ, Eckert K, McAlister VC, Chin-Yee IH. Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events. Transfus. Med. 2009; 19: 43-49.
18. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-298.
19. Thomas GO, Dutton RP, Hemlock B etal. Thromboembolic complications associated with factor VIIa administration. J. Trauma 2007; 62: 564-569.
20. Yank V, Tuohy CV, Logan AC etal. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann. Intern. Med. 2011; 154: 529-540.
21. Queensland Health Medicines Advisory Committee. Queensland Health List of Approved Medicines. Edition: Queensland Health. [Cited 26 Feb 2011] Available from URL: http://www.health.qld.gov.au/qhcss/mapsu/sdl.asp
22. Avorn J, Kesselheim A. A hemorrhage of off-label use. Ann. Intern. Med. 2011; 154: 566-567.
23. Ghinea N, Lipworth W, Kerridge I, Day R. No evidence or no alternative? Taking responsibility for off-label prescribing. Intern. Med. J. 2012; 42: 247-251.